New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:58 EDTMTU, OXM, PFG, SJM, COF, STI, TCP, NVS, FDO, BMRN, GPRE, LPL, SRE, LB, DG, ARCOOn The Fly: Analyst Upgrade Summary
Arcos Dorados (ARCO) upgraded to Buy from Underperform at BofA/Merrill... BioMarin (BMRN) upgraded to Outperform from Neutral at Credit Suisse... Capital One (COF) upgraded to Buy from Neutral at Nomura... Dollar General (DG) upgraded to Buy from Hold at Jefferies... Family Dollar (FDO) upgraded to Buy from Hold at Jefferies... J.M. Smucker (SJM) upgraded to Market Perform from Underperform at Wells Fargo... L Brands (LB) upgraded to Perform from Underperform at Oppenheimer... Novartis (NVS) upgraded to Equalweight from Underweight at Barclays... Principal Financial (PFG) upgraded to Equal Weight from Underweight at Morgan Stanley... Sempra Energy (SRE) upgraded to Buy from Neutral at ISI Group... TC PipeLines (TCP) upgraded to Equal Weight from Underweight at Barclays... Oxford Industries (OXM) upgraded to Buy from Neutral at Sidoti... LG Display (LPL) upgraded to Outperform from Neutral at Macquarie... SunTrust (STI) upgraded to Outperform from Market Perform at Keefe Bruyette... Mitsubishi UFJ (MTU) upgraded to Buy from Neutral at BofA/Merrill...Green Plains (GPRE) upgraded to Overweight from Equal Weight at Stephens.
News For ARCO;BMRN;COF;DG;FDO;SJM;LB;NVS;PFG;SRE;TCP;OXM;LPL;STI;MTU;GPRE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
November 19, 2014
15:31 EDTLBNotable companies reporting after market close
Subscribe for More Information
15:15 EDTFDO, DGDollar General affirms commitment to Family Dollar deal, says FTC review ongoing
Subscribe for More Information
15:14 EDTFDO, DGDollar General says actively engaged in ongoing FTC review process for deal
Subscribe for More Information
15:13 EDTFDO, DGDollar General affirms commitment to Family Dollar acquisition
08:31 EDTFDOFamily Dollar reschedules special meeting of shareholders to December 23
Subscribe for More Information
07:51 EDTCOFClearing House Payments Company to hold a conference
Subscribe for More Information
07:05 EDTSJMJ.M. Smucker backs FY15 EPS ex-items $5.45-$5.65, consensus $5.55
The company expects FY15 net sales to decrease approximately 1%, as compared to 2014. Revenue consensus $5.56B. Based on the full year results for the first six months of 2015, the company's outlook implies a modest increase in net sales for the last six months of 2015 over the same period last year. The company noted higher net price realization, favorable mix, and the contribution from Sahale as the primary contributors. Volume declines and an unfavorable net price realization to cost relationship in the U.S. Retail Coffee segment are the primary contributors of the income per diluted share decline for the last six months of 2015, compared to the same period in 2014. Free cash flow for 2015 is expected to approximate $500M reflecting the anticipated decrease in net income and a higher level of working capital requirements.
07:03 EDTSJMJ.M. Smucker reports Q2 EPS ex-items $1.53, consensus $1.53
Subscribe for More Information
06:39 EDTDG, FDODollar General may have to sell over 4K stores for deal approval, NY Post says
The Federal Trade Commission may require Dollar General (DG) to sell more than 4,000 of its stores to gain approval of its deal to buy Family Dollar (FDO), according to The New York Post. Dollar General had previously said that it was willing to sell 1,500 of its stores to facilitate the deal, the newspaper stated. Reference Link
November 18, 2014
15:21 EDTSJMNotable companies reporting before tomorrow's open
Subscribe for More Information
November 17, 2014
16:52 EDTNVSNovartis' LCZ696 could change course of heart failure for patients, study shows
New data on Novartis' investigational medicine, LCZ696, for patients with heart failure with reduced ejection fraction shows it has the potential to change the course of the disease for patients. In August, Novartis presented topline results from the landmark PARADIGM-HF study showing LCZ696 was superior to ACE inhibitor enalapril on key endpoints, including significantly reducing the risk of CV death or heart failure hospitalization. The new analyses being presented for the first time at the American Heart Association Scientific Sessions 2014, with a paper being simultaneously published in Circulation, show that versus enalapril, LCZ696 significantly: reduced the risk of dying suddenly by 20% in HFrEF patients 45% of CV deaths and 36% of all cause deaths are sudden; reduced first and subsequent HFrEF hospitalizations by 21% and 23% respectively; reduced hospitalizations for a cardiovascular reason or for any reason both by 16%; reduced the need for more intense treatment at home by 16%; reduced emergency room visits because of rapid symptom worsening by 30%.
11:06 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:00 EDTDGDollar General says now accepting American Express cards
Subscribe for More Information
07:47 EDTLBL Brands has strong momentum, says Oppenheimer
Subscribe for More Information
06:08 EDTCOFCapital One reports October charge-off rate 3.16% vs. 2.79% last month
Reports October 30-plus day performing delinquency rate 3.31% vs. 3.21% last month.
November 16, 2014
15:07 EDTNVSNovartis says arthritis drug secukinumab met primary endpoint
Subscribe for More Information
November 14, 2014
17:27 EDTFDOPaulson & Co. gives quarterly update on stakes
Subscribe for More Information
14:53 EDTNVSCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
12:53 EDTCOFOmega Advisors gives quarterly update on stakes
NEW STAKES: AerCap Holdings (AER), Nordic American Offshore (NAO), Melco Crown Entertainment (MPEL), Groupon (GRPN), and Ashland (ASH). INCREASED STAKES: QEP Resources (QEP), United Continental (UAL), Cabot Oil & Gas (COG), Actavis (ACT), and KAR Auction Services (KAR). DECREASED STAKES: Sprint (S), SandRidge Energy (SD), Sirius XM Holdings (SIRI), Kinder Morgan (KMI), and Transocean (RIG). LIQUIDATED STAKES: QUALCOMM (QCOM), Ocwen Financial (OCN), Freeport-McMoRan (FCX), Boston Scientific (BSX), and Capital One (COF).
07:14 EDTNVSAmerican College of Rheumatology is holding a meeting
2014 ACR/ARHP Annual Meeting is being held in Boston on November 14-19.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use